Updated lem isi
X

Given the current situation, we understand that people may experience worry and even fear about how their disease and treatment may impact their personal risk. Sanofi Genzyme is committed to patient safety and to transparent communication. We are taking COVID-19 seriously, and we are committed to updating the communities we serve with relevant information related to our medicines to help inform health decisions.

As COVID-19 has emerged only recently, there are no available data regarding the impact of the virus on our current therapies. At this time, if you have general questions about our therapies, you should consult the current U.S Prescribing Information (USPI).

Each patient’s situation is unique, and patients and their healthcare providers are in the best position to make decisions regarding their care. In addition to local public health authority guidance, and local guidance from medical or patient associations, more information about COVID-19 can be found on the Centers for Disease Control’s (CDC) website or the World Health Organization’s (WHO) website.

MAT-US-2001107

■ Sanofi Genzyme Global

INDICATION

AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Do not take AUBAGIO if you have severe liver problems, are pregnant or of childbearing potential and not using effective birth control, have had an allergic reaction to AUBAGIO or leflunomide, or are taking a medicine called leflunomide for rheumatoid arthritis. View IMPORTANT SAFETY INFORMATION

AUBAGIO® (teriflunomide) 14 mg tablet image

” Thankfully, With the $0 co-pay
program I don’t have to stress
about paying for my Treatment ”

-Ernest On AUBAGIO 14 mg • Individual experiences may vary

See Results
aubagio’s effectiveness.
Learn with Others
GET ANSWERS AT FREE EVENTS.

Patient Portrayal

A ONCE-DAILY PILL WITH A $0 CO-PAY*

The last thing you want to worry about is how to pay the cost of your treatment.

MS One to One strives to ensure financial limitations don’t prevent you from taking your AUBAGIO, and the AUBAGIO $0 Co-pay program is a key part of that.

The AUBAGIO Co-Pay Program offers assistance for those with commercial insurance. It assists with co-pay and co-insurance costs for AUBAGIO prescriptions, regardless of your financial status. Once enrolled in the program, you’ll have a $0 co-payment. Talk to an MS One to One Nurse to learn more at 1‑855‑676‑63261-855-676-6326.

Additional financial assistance.

If you do not have insurance or are unable to pay for treatment, the Sanofi Genzyme Patient Assistance Program could be the answer. Another solution: an MS One to One Nurse may be able to help you get support from not-for-profit organizations.

Talk to an MS One to One Nurse for more information and to see if you’re eligible. You may also want to check with your local patient advocacy group about other support.

AUBAGIO® $0 co-pay program

AUBAGIO $0 CO-PAY PROGRAM

Call MS One to One at 1‑855‑676‑6326. Call MS One to One at 1-855-676-6326.

Beginning Aubagio With one start®

Start within 5 business days.

With this initiation program, eligible commercially insured patients can begin treatment within 5 business days of being prescribed AUBAGIO (teriflunomide) for relapsing MS. If needed, you can receive AUBAGIO at no cost to you for up to 1 year while benefits are being verified. Please note, your healthcare provider should check off the One Start® box on the One to One Start Form when you enroll in MS One to One® to be eligible for help from One Start®.


The One Start® Program is not available for prescriptions purchased under Medicare, Medicaid, TriCare, or other federal- and state-funded programs.

Next: COMMUNITY

*Out-of-pocket costs related to medication, appointments, evaluations, testing, or other related services are not covered by the AUBAGIO Co-Pay Program. The AUBAGIO Co-Pay Program is not available for prescriptions purchased under Medicare, Medicaid, TRICARE, or other federal- and state-funded programs. Sanofi Genzyme reserves the right to amend or terminate the program.

INDICATION

AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

IMPORTANT SAFETY INFORMATION

DO NOT TAKE AUBAGIO IF YOU:
  • Have severe liver problems. AUBAGIO may cause serious liver problems, which can be life-threatening. Your risk may be higher if you take other medicines that affect your liver. Your healthcare provider should do blood tests to check your liver within 6 months before you start AUBAGIO and monthly for 6 months after starting AUBAGIO. Tell your healthcare provider right away if you develop any of these symptoms of liver problems: nausea, vomiting, stomach pain, loss of appetite, tiredness, yellowing of your skin or whites of your eyes, or dark urine.
  • Are pregnant. AUBAGIO may harm an unborn baby. You should have a pregnancy test before starting AUBAGIO. After stopping AUBAGIO, continue to use effective birth control until you have made sure your blood levels of AUBAGIO are lowered. If you become pregnant while taking AUBAGIO or within 2 years after stopping, tell your healthcare provider right away and enroll in the AUBAGIO Pregnancy Registry at 1‑800‑745‑4447, option 2.
  • Are pregnant. AUBAGIO may harm an unborn baby. You should have a pregnancy test before starting AUBAGIO. After stopping AUBAGIO, continue to use effective birth control until you have made sure your blood levels of AUBAGIO are lowered. If you become pregnant while taking AUBAGIO or within 2 years after stopping, tell your healthcare provider right away and enroll in the AUBAGIO Pregnancy Registry at 1-800-745-4447, option 2.

  • Are of childbearing potential and not using effective birth control.

    It is not known if AUBAGIO passes into breast milk. Your healthcare provider can help you decide if you should take AUBAGIO or breastfeed — you should not do both at the same time.

    If you are a man whose partner plans to become pregnant, you should stop taking AUBAGIO and talk with your healthcare provider about reducing the levels of AUBAGIO in your blood. If your partner does not plan to become pregnant, use effective birth control while taking AUBAGIO.

  • Have had an allergic reaction to AUBAGIO or a medicine called leflunomide.
  • Take a medicine called leflunomide for rheumatoid arthritis.

AUBAGIO may stay in your blood for up to 2 years after you stop taking it. Your healthcare provider can prescribe a medicine that can remove AUBAGIO from your blood quickly.

Before taking AUBAGIO, talk with your healthcare provider if you have: liver or kidney problems; a fever or infection, or if you are unable to fight infections; numbness or tingling in your hands or feet that is different from your MS symptoms; diabetes; serious skin problems when taking other medicines; breathing problems; or high blood pressure. Your healthcare provider will check your blood cell count and TB test before you start AUBAGIO. Talk with your healthcare provider if you take or are planning to take other medicines (especially medicines for treating cancer or controlling your immune system), vitamins or herbal supplements.

AUBAGIO may cause serious side effects, including: reduced white blood cell count — this may cause you to have more infections; numbness or tingling in your hands or feet that is different from your MS symptoms; allergic reactions, including serious skin problems; breathing problems (new or worsening); and high blood pressure. Patients with low white blood cell count should not receive certain vaccinations during AUBAGIO treatment and 6 months after.

Tell your doctor if you have any side effect that bothers you or does not go away.

The most common side effects when taking AUBAGIO include: headache; diarrhea; nausea; hair thinning or loss; and abnormal liver test results. These are not all the side effects of AUBAGIO. Tell your healthcare provider about any side effect that bothers you.

Consult your healthcare provider if you have questions about your health or any medications you may be taking, including AUBAGIO.

Please click here for full Prescribing Information, including boxed WARNING and Medication Guide.

IMPORTANT SAFETY INFORMATION
Do not take AUBAGIO if you have severe liver problems. AUBAGIO may cause serious liver problems, which can be life-threatening. Your risk may be higher if you take other medicines that affect your liver. View More